Tempus 3D Tumor Organoid (TO) Screening

Fixed panels:

• PanKRAS: 40 TOs featuring diverse KRAS mutations and wild-type controls, suitable for assets targeting KRAS
• PanCRC: 40 colorectal cancer (CRC) TOs enriched for pre-treated models, suitable for assets intended as 2L/3L therapies

Key insights:

• TO viability assessments via luminescence readouts
• Responses to indication-specific standard of care (SOC) therapies
• Molecular characterization of each organoid at baseline with Tempus xT & xR NGS assays (648 gene, full transcriptome)
• Bioinformatics to uncover insights such as biomarkers, target indications, and drivers of drug response/resistance

Seamlessly synergize biomarkers uncovered with Tempus Explore. Our expert data scientists and computational biologists leverage our vast real-world data (RWD) library to generate and further validate hypotheses across 1,000,000+ records with matched clinical data linked with genomic information.

Enrollment is open through December 20, 2024. Space is limited – complete the form now to secure your spot.